Zook In As Vivus CEO, But Turnaround Depends On Partnering
This article was originally published in The Pink Sheet Daily
Executive Summary
Vivus has a new chairman and CEO after a proxy battle with a dissident shareholder ended in a settlement, but will the new management be able to find a marketing partner for Qsymia or broker an outright sale?
You may also be interested in...
Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking
The summary report of an interim analysis of the ongoing LIGHT clinical trial evaluating the cardiovascular safety of the obesity medicine can form the basis of a resubmission of the Contrave NDA, the company announced, shaving some time off the PDUFA clock.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.